Marker Therapeutics is a highly innovative, clinical-stage immuno-oncology company pioneering non-genetically modified Multi-Antigen Recognizing (MAR)-T cell therapies. Unlike traditional CAR-T therapies, Marker's MAR-T platform targets up to six tumor-associated antigens simultaneously without genetic engineering, significantly reducing toxicity (no cytokine release syndrome or ICANS observed to date) and limiting tumor escape. The company's lead candidate, MT-601, has demonstrated exceptional clinical efficacy in its Phase 1 APOLLO trial for relapsed lymphoma, achieving a 66% objective response rate (ORR) and a 50% complete response rate (CRR) in patients who failed or were ineligible for CD19 CAR-T therapies. Furthermore, its expansion into solid tumors (pancreatic cancer) is backed by strong pre-clinical and clinical proof-of-concept data showing an 84.6% disease control rate when combined with frontline chemotherapy. While the company faces near-term cash runway constraints (funded into Q1 2027) and going concern risks typical of micro-cap biotech, its clean, debt-free balance sheet and substantial non-dilutive grant support (NIH, CPRIT, FDA) make it an attractive high-upside speculative play with significant valuation expansion potential upon upcoming clinical readouts.